Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Previously, we identified that elevated soluble T-cell immunoglobulin and mucin domain-containing protein 3 (sTim-3) was significantly associated with allograft dysfunction in kidney transplant recipients (KTRs). However, its roles in native chronic kidney disease (CKD), relationship with kidney histological lesions, and association with adverse outcomes in patients with kidney diseases remain unexplored.
This study included three cohorts. KTR cohort comprised 108 KTRs who underwent indicative allograft biopsies and 37 KTRs with stable renal function. CKD cohort consisted of 286 native CKD patients, including 122 with biopsy-confirmed membranous nephropathy (MN) and 164 with IgA nephropathy (IgAN). KTR-dyna cohort involved 44 KTRs who had one-year regular follow-up after transplantation. Pre-biopsy plasma samples were collected from KTR and CKD cohorts, and serial collections were performed in KTR-dyna cohort. sTim-3 levels were quantified using ELISA.
sTim-3 levels were significantly associated with renal function markers in both KTR and native CKD patients, with correlation coefficients ranging from 0.62 to 0.79 in the KTR cohort and 0.38 to 0.54 in the CKD cohort. In the KTR-dyna cohort, a significant reduction in sTim-3 concentrations was observed post-transplantation, inversely correlating with eGFR improvement. sTim-3 levels increased progressively with advancing severity of tubulointerstitial fibrosis and tubular atrophy (IF/TA), fibrotic interstitial inflammation, arteriolar sclerosis and microvascular inflammation, but showed minimal correlation with glomerular injury (Figure 1). Notably, sTim-3 independently correlated with IF/TA severity and showed strong discriminative capacity for moderate-to-severe kidney fibrosis (AUC: 0.72-0.83) in both KTRs and CKDs. Cox regression analysis demonstrated that elevated sTim-3 levels were significantly associated with graft failure and eGFR decline in KTRs (Figure 2). These associations maintained after adjusting for recipient and donor characteristics as well as histological features, but not for renal function markers.
Plasma sTim-3 is a promising biomarker for kidney dysfunction and tubulointerstitial damage, demonstrating predictive value for adverse outcomes across transplant and native CKD settings.
